ES2786374T3 - Compuesto antimicótico - Google Patents

Compuesto antimicótico Download PDF

Info

Publication number
ES2786374T3
ES2786374T3 ES15817507T ES15817507T ES2786374T3 ES 2786374 T3 ES2786374 T3 ES 2786374T3 ES 15817507 T ES15817507 T ES 15817507T ES 15817507 T ES15817507 T ES 15817507T ES 2786374 T3 ES2786374 T3 ES 2786374T3
Authority
ES
Spain
Prior art keywords
methyl
tetrahydrofuran
methoxy
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15817507T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Christopher Colley
Kazuhiro Ito
Garth Rapeport
Peter Strong
Peter John Murray
Stuart Thomas Onions
Mihiro Sunose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmocide Ltd
Original Assignee
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmocide Ltd filed Critical Pulmocide Ltd
Application granted granted Critical
Publication of ES2786374T3 publication Critical patent/ES2786374T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F1/00—Details not covered by groups G06F3/00 - G06F13/00 and G06F21/00
    • G06F1/26—Power supply means, e.g. regulation thereof
    • G06F1/32—Means for saving power
    • G06F1/3203—Power management, i.e. event-based initiation of a power-saving mode
    • G06F1/3234—Power saving characterised by the action undertaken
    • G06F1/325—Power saving in peripheral device
    • G06F1/3268—Power saving in hard disk drive
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C11/00—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor
    • G11C11/21—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements
    • G11C11/34—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices
    • G11C11/40—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices using transistors
    • G11C11/401—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices using transistors forming cells needing refreshing or charge regeneration, i.e. dynamic cells
    • G11C11/4063—Auxiliary circuits, e.g. for addressing, decoding, driving, writing, sensing or timing
    • G11C11/407—Auxiliary circuits, e.g. for addressing, decoding, driving, writing, sensing or timing for memory cells of the field-effect type
    • G11C11/4074—Power supply or voltage generation circuits, e.g. bias voltage generators, substrate voltage generators, back-up power, power control circuits

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES15817507T 2014-12-05 2015-12-04 Compuesto antimicótico Active ES2786374T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14196662 2014-12-05
PCT/GB2015/053733 WO2016087880A1 (en) 2014-12-05 2015-12-04 Antimycotic compound

Publications (1)

Publication Number Publication Date
ES2786374T3 true ES2786374T3 (es) 2020-10-09

Family

ID=52006914

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15817507T Active ES2786374T3 (es) 2014-12-05 2015-12-04 Compuesto antimicótico
ES15808770T Active ES2790875T3 (es) 2014-12-05 2015-12-04 Compuesto antimicótico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15808770T Active ES2790875T3 (es) 2014-12-05 2015-12-04 Compuesto antimicótico

Country Status (18)

Country Link
US (12) US10106531B2 (enExample)
EP (2) EP3227278B1 (enExample)
JP (2) JP6669751B2 (enExample)
KR (1) KR102579848B1 (enExample)
CN (2) CN112375073B (enExample)
AU (1) AU2015356795B2 (enExample)
BR (1) BR112017008481B1 (enExample)
CA (1) CA2963625C (enExample)
DK (2) DK3227277T3 (enExample)
EA (1) EA033736B1 (enExample)
ES (2) ES2786374T3 (enExample)
HU (2) HUE048905T2 (enExample)
IL (1) IL251631B (enExample)
MX (1) MX370412B (enExample)
PL (1) PL3227277T3 (enExample)
PT (1) PT3227277T (enExample)
SG (1) SG11201702835RA (enExample)
WO (2) WO2016087880A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016087880A1 (en) * 2014-12-05 2016-06-09 Pulmocide Limited Antimycotic compound
US10160772B2 (en) 2014-12-18 2018-12-25 Pulmocide Limited 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
ES2790723T3 (es) 2015-05-21 2020-10-29 Pulmocide Ltd Antifúngico 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-il)metil)-5-(2,4-difluorofenil)tetrahidrofurano-3-il)metoxi)-3-metilfenil)piperazina-1-il)-N -(2-hidroxiciclohexil)benzamida, o una sal farmacéuticamente aceptable del mismo
WO2017093491A1 (en) * 2015-12-04 2017-06-08 Pulmocide Limited Antimycotic triazole compound
CN110198707A (zh) * 2016-11-28 2019-09-03 赛力克斯生物私人有限公司 用于治疗口腔感染性疾病的组合物和方法
US11185548B2 (en) 2016-12-23 2021-11-30 Helmholtz Zentrum Munchen—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases
GB201917867D0 (en) * 2019-12-06 2020-01-22 Pulmocide Ltd Polymorphs
EP3858357A1 (en) * 2020-01-28 2021-08-04 Diaccurate Use of azole compounds to stimulate the immune system and as inhibitors for s-pla2gib
RU2770598C1 (ru) * 2021-06-29 2022-04-18 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) ПРИМЕНЕНИЕ ПРОТИВОГРИБКОВОГО СРЕДСТВА НА ОСНОВЕ 2-((4-R1-5-R2-3-(ЭТОКСИКАРБОНИЛ)ТИОФЕН-2-ИЛ)АМИНО)-4-ОКСО-4-R3-БУТ-2-ЕНОВЫХ КИСЛОТ ПО ОТНОШЕНИЮ К Candida aldicans
TW202541814A (zh) 2023-11-30 2025-11-01 瑞士商巴塞利亞阿爾斯維爾藥業國際股份有限公司 用於治療真菌感染的藥物組合

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5533466A (en) * 1978-07-14 1980-03-08 Janssen Pharmaceutica Nv Novel azole derivatives and their manufacture
CH655103A5 (de) * 1983-03-11 1986-03-27 Sandoz Ag Azolderivate, verfahren zu ihrer herstellung und ihre verwendung.
CA1292472C (en) 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
DE3609598A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
AU2811689A (en) 1987-11-20 1989-06-14 Schering Corporation Tri-and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5039678A (en) 1989-03-23 1991-08-13 Wake Forest University Method of increasing cranial vessel proliferation by administering nimodipine
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5403937A (en) * 1993-04-30 1995-04-04 Schering Corporation Process for preparing intermediates for the synthesis of antifungal agents
US5714490A (en) 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
DK0736030T3 (da) 1993-12-21 2001-10-29 Schering Corp Fungicide tetrahydrofuraner
US5486625A (en) 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
ES2199291T3 (es) 1995-06-02 2004-02-16 Schering Corporation Antifungicos de tetrahidrofurano.
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
PL212985B1 (pl) 2001-04-03 2012-12-31 Schering Corp Ciekla zawiesina zawierajaca przeciwgrzybiczo skuteczna ilosc posakonazolu oraz zastosowanie zmikronizowanych czastek posakonazolu
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
WO2013012848A1 (en) * 2011-07-18 2013-01-24 Merck Patent Gmbh Benzamides
WO2013036866A1 (en) 2011-09-07 2013-03-14 The Johns Hopkins University Itraconazole analogs and use thereof
WO2016087880A1 (en) * 2014-12-05 2016-06-09 Pulmocide Limited Antimycotic compound
GB201917867D0 (en) 2019-12-06 2020-01-22 Pulmocide Ltd Polymorphs

Also Published As

Publication number Publication date
US10800762B2 (en) 2020-10-13
MX2017007188A (es) 2017-08-28
JP6666345B2 (ja) 2020-03-13
CA2963625A1 (en) 2016-06-09
AU2015356795A1 (en) 2017-04-27
PT3227277T (pt) 2020-04-14
US20210238169A1 (en) 2021-08-05
US20170320858A1 (en) 2017-11-09
ES2790875T3 (es) 2020-10-29
NZ730861A (en) 2021-04-30
CA2963625C (en) 2023-08-22
EA201791174A1 (ru) 2017-10-31
DK3227278T3 (da) 2020-04-27
HUE048905T2 (hu) 2020-08-28
US10858345B2 (en) 2020-12-08
IL251631B (en) 2020-05-31
HUE048685T2 (hu) 2020-07-28
CN107001343A (zh) 2017-08-01
US20210048874A1 (en) 2021-02-18
KR102579848B1 (ko) 2023-09-18
US10344022B2 (en) 2019-07-09
US20200239453A1 (en) 2020-07-30
US10450304B2 (en) 2019-10-22
US20190023697A1 (en) 2019-01-24
SG11201702835RA (en) 2017-05-30
US20230295133A1 (en) 2023-09-21
US20200002320A1 (en) 2020-01-02
WO2016087878A1 (en) 2016-06-09
BR112017008481B1 (pt) 2022-09-06
EA033736B1 (ru) 2019-11-20
US12269814B2 (en) 2025-04-08
JP6669751B2 (ja) 2020-03-18
BR112017008481A2 (pt) 2018-01-09
PL3227277T3 (pl) 2020-08-10
JP2017536385A (ja) 2017-12-07
US20190023696A1 (en) 2019-01-24
US20200031809A1 (en) 2020-01-30
US11661415B2 (en) 2023-05-30
IL251631A0 (en) 2017-06-29
DK3227277T3 (da) 2020-04-27
US20200399253A1 (en) 2020-12-24
CN107001343B (zh) 2020-12-11
US10093659B2 (en) 2018-10-09
US10106531B2 (en) 2018-10-23
KR20170088850A (ko) 2017-08-02
MX370412B (es) 2019-12-11
US11008307B2 (en) 2021-05-18
US20170037035A1 (en) 2017-02-09
CN112375073A (zh) 2021-02-19
AU2015356795B2 (en) 2020-01-16
US10662179B2 (en) 2020-05-26
US10487073B2 (en) 2019-11-26
WO2016087880A1 (en) 2016-06-09
EP3227277B1 (en) 2020-02-05
US20190276441A1 (en) 2019-09-12
HK1244795A1 (en) 2018-08-17
EP3227277A1 (en) 2017-10-11
EP3227278A1 (en) 2017-10-11
CN112375073B (zh) 2024-04-16
JP2017536382A (ja) 2017-12-07
EP3227278B1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
US12269814B2 (en) Process for preparing a compound useful to treat mycoses
US20190202813A1 (en) Process for preparing 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-N-((1S,2S)-2-hydroxycyclohexyl)benzamide or a pharmaceutically acceptable salt thereof
NZ730861B2 (en) Antimycotic compound
BR112017020807B1 (pt) Composto 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-il)metil)-5-(2,4- difluorofenil)tetra-hidrofuran-3-il)metóxi)-3-metilfenil)piperazin-1-il)-n-(2- hidroxiciclo-hexil) benzamida antifúngica, seu processo de preparação, e composição farmacêutica
HK1252779B (en) Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1-yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof